SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

E-Cigarettes, Vaping, and Tobacco: Scoping Review with ☸️SAIMSARA.

Longevity icon

Longevity & Public Health

Issue 2, Volume 1, 2026

DOI: 10.62487/saimsara7a9d22b6

Editorial note
• Last update: 2026-05-13 07:23:01
What is this paper about
E-cigarettes may reduce selected harms when they fully replace combustible tobacco, but this evidence map shows why they cannot be treated as harmless nicotine products. The full SAIMSARA evidence map gives human- and machine-readable access to 123 references, clarifying substitution benefits, dual-use risks, youth uptake, toxicology, vascular and airway effects, pregnancy signals, and regulatory implications.
Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Evidence preview · Did you know?
Realistic clinical-public-health scene showing an adult smoker switching from combustible cigarettes to vaping.

Substitution can change exposure

Did you know? In experienced e-cigarette users, 78% reported no tobacco use in the previous 30 days.

That is the harm-reduction signal: benefit appears strongest when vaping fully replaces combustible cigarettes.

Realistic youth public-health scene showing vaping products, social media influence, and tobacco-risk awareness.

The youth signal is not small

Did you know? Adolescent susceptibility to e-cigarettes was 36.6%, higher than cigarette susceptibility at 27.8%.

This makes e-cigarettes a possible nicotine entry point, not only a smoking-reduction tool.

Realistic regulatory-toxicology scene showing vaping devices, laboratory testing, and public-health oversight.

Not harmless vapor

Did you know? Long-term e-cig exposure in mice induced lung adenocarcinomas in 22.5% and bladder urothelial hyperplasia in 57.5%.

This is not direct human cancer proof, but it is a strong reason for long-term toxicology and regulatory caution.

Swipe sideways on mobile · full evidence map opens after unlock

Abstract: To map and synthesize original studies addressing e-cigarettes in relation to tobacco products, with emphasis on comparative exposure, dependence, cessation or substitution, biological toxicity, population uptake, misperceptions, and regulatory implications. The review uses 123 references and builds its evidence map from 123 original studies with 8769068 total participants/sample observations (topic-deduplicated ΣN). The evidence mapped here suggests that e-cigarettes occupy a harm-reduction position relative to combustible tobacco but are not biologically inert, with full substitution linked to reduced exhaled CO and craving in resistant smokers yet sustained nicotine dependence, dual use, and measurable airway, vascular, and developmental toxicity across experimental models. Comparative pharmacokinetic data indicating peak plasma nicotine of 24.0 ng/mL for cigarettes versus 8.0 ng/mL for pod e-cigs highlight that nicotine delivery, abuse liability, and toxicant profiles vary substantially by device, flavor, and formulation. Adolescent susceptibility reaching 36.6% for e-cigs in one Italian sample underscores that population-level uptake risks coexist with potential adult substitution benefits. Clinically, this supports cautious, product-specific counseling rather than blanket endorsement or prohibition. Future research should prioritize long-term prospective cohorts distinguishing exclusive switching from dual use, with harmonized exposure metrics linking device characteristics to durable cardiopulmonary and dependence outcomes.

Keywords: E-cigarettes; Tobacco; Vaping; Nicotine; Heated tobacco products; Dual use; Smoking cessation; Adolescents; Aerosol exposure; Cardiovascular effects

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (123)